Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul;14(7):1917-1928.
doi: 10.1007/s13555-024-01204-1. Epub 2024 Jun 25.

Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis

Lyn Guenther  1 , Irina Turchin  2   3   4 , Ron Vender  5 , Lorne E Albrecht  6 , Catherine Maari  7 , Howard Yanofsky  8 , Vimal H Prajapati  4   9   10   11   12   13
Affiliations

Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis

Lyn Guenther et al. Dermatol Ther (Heidelb). 2024 Jul.

Abstract

Introduction: An expert panel of Canadian dermatologists was assembled to develop consensus statements regarding the current landscape of topical therapies for plaque psoriasis and the place in therapy of the recently approved fixed-dose combination halobetasol propionate (HP)/tazarotene (TAZ) lotion (HP/TAZ) in the treatment algorithm for plaque psoriasis.

Method: A modified nominal group technique, which combined both independent and group input from the expert panel, was used to develop the consensus statements. The expert panel completed surveys to elicit their independent views on the current landscape of topical therapies for plaque psoriasis in Canada. The first expert panel session was held to discuss the existing body of literature and develop draft consensus statements about topical therapies and the place in therapy of HP/TAZ. Independent feedback on the draft consensus statements was solicited from expert panel members prior to another expert panel session where the amended consensus statements were further discussed, edited and, finally, voted on.

Results: The expert panel reached consensus on 20 statements.

Conclusion: Expert panel members agreed, based on the existing body of literature, that there is a place in therapy for HP/TAZ to address several current unmet treatment needs of patients with plaque psoriasis. Studies have shown that HP/TAZ is an effective and safe first-line treatment for moderate-to-severe plaque psoriasis. Due to its cosmetically pleasing vehicle and once-daily administration, HP/TAZ may improve patient acceptance and treatment adherence.

Keywords: Consensus; Corticosteroid; Halobetasol; Plaque psoriasis; Retinoid; Tazarotene; Topical therapy.

PubMed Disclaimer

Conflict of interest statement

L. Guenther is on the Speaker’s Bureau of, a consultant for, and/or has received grant/research support from Abbvie, Altana, Amgen, Aslan, Bausch Health, Boehringer Ingelheim, BMS, Celgene, Eli Lilly and Company, Galderma, GSK, Innovaderm, Janssen, Leo Pharma, Merck Frosst, Novartis, Pfizer, Sandoz, Sun Pharma, and UCB. I. Turchin has been advisor, consultant, speaker and/or investigator for Abbvie, Amgen, Arcutis, Aristea, Bausch Health, BMS, Boehringer Ingelheim, Celgene, Eli Lilly and Company, Galderma, Incyte, Janssen, Kiniksa, LEO Pharma, Mallinckrodt, Novartis, Pfizer, Sanofi Genzyme, Sun Pharma, and UCB. R. Vender has received grants and/or research support from, is on the Speaker’s Bureau for, received honoraria from, and/or is a consultant for Abbvie, Actelion, Amgen, Aralez, Arcutis, Bausch Health, Boehringer Ingelheim, BMS, Celgene, Centocor, Cipher, Dermira, Dermavant, Galderma, GSK, Innovaderm, Janssen, Kabi-Care, Leo, Eli Lilly and Company, Meiji, Merck, Novartis, Palladin, Pfizer, Regeneron, Sandoz, Sun Pharma, Takeda, UCB, and Viatris-Mylan. L. Albrecht is on the Speaker’s Bureau of, a consultant for, and/or has received grant/research support or honoraria from Abbvie, Akros, Amgen, Arcutis, Avillion, Bausch Health/Valeant, Boehringer Ingelheim, BMS, Celgene, Centocor, Cutanea, Dermavant, Dermira, Eli Lilly and Company, Galderma, Glenmark, Hoffman-La Roche, Janssen, LEO Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, UCB, and Valeant/Bausch Health. C. Maari has received honoraria from Bausch Health, Canada Inc. H. Yanofsky has received honoraria from Bausch Health, Canada Inc. V.H. Prajapati has been an advisor, consultant, speaker, and/or investigator for AbbVie, Actelion, Amgen, AnaptysBio, Apogee Therapeutics, Aralez, Arcutis, Arena, Asana, Aspen, Bausch Health/Valeant, Boehringer Ingelheim, BMS, Celgene, Cipher, Concert, CorEvitas, Dermavant, Dermira, Eli Lilly and Company, Galderma, GSK, Homeocan, Incyte, Janssen, LEO Pharma, Medexus, Nimbus Lakshmi, Novartis, Organon, Pediapharm, Pfizer, RAPT Therapeutics, Regeneron, Reistone, Sanofi Genzyme, Sun Pharma, Takeda, Tribute, and UCB.

Figures

Fig. 1
Fig. 1
Consensus statements development process. HP/TAZ Halobetasol propionate 0.01%/tazarotene 0.045% lotion
See this image and copyright information in PMC

References

    1. Papp K, Gulliver W, Lynde C, Poulin Y, Ashkenas J. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg. 2011;15(4):210–9. 10.2310/7750.2011.10066. 10.2310/7750.2011.10066 - DOI - PubMed
    1. Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2022;148(1):95–102. 10.1001/archdermatol.2011.1410.10.1001/archdermatol.2011.1410 - DOI - PubMed
    1. Papp K, Valenzuela F, Poulin Y, Bernstein G, Wasel N. Epidemiology of moderate-to-severe plaque psoriasis in a Canadian surveyed population. J Cutan Med Surg. 2010;14(4):167–74. 10.2310/7750.2010.09066. 10.2310/7750.2010.09066 - DOI - PubMed
    1. Papp KA, Gniadecki R, Beecker J, et al. Psoriasis prevalence and severity by expert elicitation. Dermatol Ther (Heidelb). 2021;11(3):1053–64. 10.1007/s13555-021-00518-8. 10.1007/s13555-021-00518-8 - DOI - PMC - PubMed
    1. Elmets CA, Korman NJ, Prater F, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2020;84(2):432–70. 10.1016/j.jaad.2020.07.087. 10.1016/j.jaad.2020.07.087 - DOI - PubMed